Company Filing History:
2 out of 451 
2 out of 159 Years Active: 2022-2023
Title: Inventor Spotlight: Dov Pechenick
Introduction
Dov Pechenick is a notable inventor based in New Hampton, NH, recognized for his significant contributions to the field of immunology. With two patents under his name, Pechenick's innovations have the potential to impact treatments for various health conditions.
Latest Patents
Among his recent inventions is a groundbreaking patent titled "Anti-human VISTA antibodies and use thereof." This invention presents both antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. The antagonist antibodies are designed to inhibit or block VISTA's suppressive effects on T cell immunity, ultimately promoting T cell immunity. Conversely, the agonist antibodies are formulated to enhance or mimic VISTA's effects, thereby suppressing T cell immunity. Notably, these antibodies and their fragments hold promise for treating cancer, infectious conditions, autoimmunity, allergy, inflammatory conditions, GVHD, sepsis, and supporting transplant recipients. The patent also encompasses screening assays aimed at identifying these agonists, further aiding in the development of targeted therapies.
Career Highlights
Pechenick's career includes significant roles at prominent companies, specifically Immunex Corporation and Janssen Pharmaceuticals, Inc. These experiences have provided him with a robust foundation in biotechnology and drug development, fueling his innovative spirit and shaping his research focus in immunotherapy.
Collaborations
Throughout his career, Dov Pechenick has collaborated with esteemed colleagues such as Michael Molloy and Jay Rothstein. These partnerships have likely contributed to the depth and breadth of his research, enhancing the overall impact of his inventions in the realm of immunology.
Conclusion
Dov Pechenick stands out as an influential inventor whose work on anti-human VISTA antibodies could revolutionize treatments for various medical conditions. His dedication to advancing immunotherapy through innovative research and collaboration exemplifies the spirit of invention, paving the way for future discoveries that may significantly improve patient outcomes.